API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/09/21/2747207/0/en/Commercial-Manufacturing-of-Eftilagimod-Alpha-at-2000L-Scale-Granted-Authorization-for-Clinical-Trial-Use.html
https://www.onclive.com/view/tacti-002-data-show-antitumor-activity-with-second-line-eftilagimod-alpha-and-pd-1-inhibition-in-hnscc
https://www.globenewswire.com/news-release/2023/05/17/2670943/0/en/Immutep-s-Efti-in-Combination-with-Pembrolizumab-Achieves-Excellent-Initial-Overall-Survival-Benefit-in-1st-Line-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2023/05/01/2658261/0/en/Immutep-Receives-Approval-to-Initiate-INSIGHT-005-Trial-Evaluating-Eftilagimod-Alpha-and-Anti-PD-L1-Therapy-BAVENCIO.html
https://www.globenewswire.com//news-release/2022/12/08/2570212/0/en/Immutep-Successfully-Achieves-Commercial-Scale-in-Manufacturing-of-Eftilagimod-Alpha.html
https://www.globenewswire.com/news-release/2022/11/09/2552010/0/en/Immutep-Granted-New-Patents-in-Japan-and-South-Korea-for-First-in-Class-LAG-3-Candidate-Eftilagimod-Alpha-in-Chemo-Immunotherapy-Combination.html
https://www.globenewswire.com/news-release/2022/10/04/2527727/0/en/Immutep-Receives-FDA-Fast-Track-Designation-for-LAG-3-Therapeutic-Eftilagimod-Alpha-for-First-Line-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2022/09/06/2510325/0/en/Immutep-Announces-Investigator-Initiated-Phase-II-Trial-Evaluating-LAG-3-Candidate-Eftilagimod-Alpha-Efti-in-Soft-Tissue-Sarcoma.html
https://www.globenewswire.com/news-release/2022/08/30/2506691/0/en/Immutep-Granted-Japanese-Patent-for-Eftilagimod-Alpha-a-Soluble-Lag-3-Protein-in-Combination-with-a-PD-1-Pathway-Inhibitor.html
https://www.biospace.com/article/releases/immutep-granted-chinese-patent-for-eftilagimod-alpha-a-soluble-lag-3-fusion-protein-in-combination-with-a-pd-1-pathway-inhibitor/?s=71
https://www.globenewswire.com/news-release/2021/08/31/2289139/0/en/Immutep-s-Chinese-Partner-Eoc-Pharma-Expands-Efti-Trial-Pipeline.html
https://www.onclive.com/view/fda-grants-fast-track-status-to-eftilagimod-alpha-for-frontline-recurrent-metastatic-head-and-neck-cancer